Arvinas Names Angela Shen CMO
This article was originally published in Scrip
US biotech company Arvinas LLC, which is developing small-molecule drugs based on targeted protein degradation, has named Angela Shen chief medical officer. She previously worked with Novartis Oncology as global clinical program head and helped launch the CTL019 (CART-19) cell and gene therapy program. Shen was clinical lead at Novartis for the development of new oncology assets and also held a medical affairs role at Johnson & Johnson.